Cannabics Pharmaceuticals Inc. (OTC-QB: CNBX) today announced it has established a Genetic lab that will develop diagnostic tools based on human genome, tumor genetics and cannabinoids.
The company recruited Dr. Moran Grinberg to serve as its VP of R&D and to lead the Genetic research. Moran has a PhD in Virology and MSc in clinical pharmacology with vast experience in conceptualizing and executing pharmacological research.
Dr. Eyal Ballan, Co-founder and CTO, said: “Our mission is to commercialize a wide range of diagnostic tools that incorporate novel technologies to retrieve better outcomes of cannabinoid treatments. Understanding the genetics of cancer-cannabinoids relations complements our CTC cell count and drug sensitivity capabilities. We are pleased to have Dr. Moran Grinberg in our team and looking forward to joining forces.”
Cannabics Pharmaceuticals Inc. (OTC-QB: CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
credit:420intel.com